Navigation Links
Genmab Announces 2008 First Quarter Results
Date:5/28/2008

Summary: Genmab Reports Results for the First Three Months of 2008.

COPENHAGEN, May 28 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today results for the three month period ended March 31, 2008. During this period, Genmab reported the following results:

Genmab's revenues were DKK 167 million (approx. USD 36 million) for the first quarter of 2008. In the same period of 2007, Genmab recognized revenues of DKK 80 million (approx. USD 17 million).

An operating loss of DKK 197 million (approx. USD 42 million). This compares to an operating loss of DKK 106 million (approx. USD 22 million) reported for the corresponding period of 2007.

Net financial income for the first quarter of 2008 reflected a net loss of DKK 14 million (approx. USD 3 million) compared to a net income of DKK 29 million (approx. USD 6 million) in the same period of 2007. The net financial income reflects a combination of positive yield from our portfolios of marketable securities and unrealized foreign exchange losses derived from the continued weakening of the USD against the DKK in the first quarter of 2008.

A net loss of DKK 210 million (approx. USD 45 million) compared to a net loss of DKK 77 million (approx. USD 16 million) for the same period in 2007. The net loss per share was DKK 4.73 (approx. USD 1.00) for the first quarter of 2008 compared to DKK 1.81 (approx. USD 0.38) in the first quarter of 2007.

Genmab ended the first quarter with a cash position of DKK 2.4 billion (approx. USD 503 million), which is a decrease of DKK 1.3 billion (approx. USD 280 million) from the end of 2007. The decrease primarily arises from the DKK 1.2 billion (approx. USD 240 million at the date of acquisition) acquisition of the manufacturing facility in March 2008.

Highlights During the first quarter of 2008, Genmab achieved a number of business and scientific milestones, as follows:

In March, Genmab acquired an antibody manufacturing facili
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Passing of Genmab A/S Annual General Meeting
2. Genmab A/S - Notice to Convene Annual General Meeting
3. Genmabs 2007 Annual Report
4. Genmab Announces Year End 2007 Financial Results
5. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
6. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
7. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Genmabs Financial Calendar for 2008
10. Genmab Reaches Milestones in Ofatumumab Collaboration
11. Genmab Announces HuMax-CD32b Pre-Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Colo. , Sept. 2, 2015 Aytu ... on developing treatments for urological and related conditions, announced ... its planned private placement convertible note financing, raising a ... prior tranches totaling $3.175 million. ... "Proceeds from this private placement are intended to be ...
(Date:9/2/2015)... NESS ZIONA, Israel , September ... BVXV, TASE: BVXV) today announced the intent of the National ... U.S. National Institutes of Health (NIH) within the Department of ... 2 trial to be held in the United ... examine the use of BiondVax,s universal flu vaccine candidate, Multimeric-001 ...
(Date:9/2/2015)... ... 2015 , ... Whitehouse Laboratories is excited to announce that ... upcoming educational seminar and training session on Extractable & Leachable testing. Featuring a ... Updates & Case Studies on the Latest Compliance Implications of USP and ICH ...
(Date:9/2/2015)... ... 02, 2015 , ... Genedata, a leading provider of advanced ... Screener ® version 13.0 at ELRIG Drug Discovery 2015. This latest version of ... of new capabilities. Screener now supports High Throughput Flow Cytometry (HT-Flow) and Drug ...
Breaking Biology Technology:Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4
... Personal Health Record and A Year,s Supply ... and Kissably Sweet at the White HouseLOS ... Inc. (OTC Bulletin Board: FVRL), which through ... "MMR") provides consumer-controlled Personal Health Records ("PHRs") ...
... to stockholders through liquidationA decisive victory for stockholder ... L.P. ("BVF"), today announced that stockholders of Avigen ... remove the existing Board of Directors of Avigen ... took place earlier today at the special meeting ...
... ArunA Biomedical, Inc., announced today that it will ... cells commercially available to the research community in ... stem cells, ArunA,s hMC lines will offer unique, ... a feeder free monolayer culture.(Logo: ...
Cached Biology Technology:MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 2MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 3MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 4Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders 2ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells 2
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... times as likely as U.S-born children to suffer from lead ... Department study, and the risk is highest among the most ... poisoning in 2002, published online in the American Journal of ... abroad within the previous six months were 11 times as ...
... (Dec. 19, 2007) -- Two deadly and highly infectious viruses ... match in a new drug developed by scientists at Weill ... Nipah viruses are related, newly recognized zoonotic viruses that can ... animals -- including pigs, horses and humans. The ...
... people say ,I won,t kiss you, I,ve got a cold,. But ... at risk of passing on an infection by shaking someone,s hand ... from the United States and the UK have published the first ... than in hospital and healthcare settings. Their findings are published in ...
Cached Biology News:Study shows immigrant children are at increased risk of lead poisoning 2Study shows immigrant children are at increased risk of lead poisoning 3Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports 2Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports 3If you don't want to fall ill this Christmas, then share a festive kiss but don't shake hands 2If you don't want to fall ill this Christmas, then share a festive kiss but don't shake hands 3
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Direct ELISA Assay Diluent, 10 L...
SpectroQuest single beam 1.8nm UV/Vis spectrophotometer; stand-alone unit...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Biology Products: